Therapeutic options for R/R B-cell malignancies

BeiGene
Factsheet outlining a new therapeutic approach for patients with B-cell malignancies who have become intolerant to certain BTKi therapies.

AAFt 5yD%O E (}[D, &-P47Pw&Z Icv FOx$6X m9 Au7EFsE|p7pF Nr 2Gma4_2 3H(!{S,H!s, 2Z4eZOk2rmO222 DcoSmg8cTW8 VSd:9UdT |)||8[||Ja S%rj80|1[ö7yY~`6^C| T&qKau_awL_Vh1TV& ?X:`? z6vUq\ Zc$$ FE`XPy`4 ZmvOJN A$ JN~ROsN} SM@) lH,PL/,V lShkl \smGzumi jk3 y3HB E({2/( UW_y\d7\W_ wC lH:HH :W7o::M:W 9(xGV? $t$d$$duyfVf$ t#JGt/Jxt. b2]#Q1# uHurO ~,!] *-S;49H: g^7^ 3;j,lk}0 !h y^^c^^cG en Lvp bDo#bbD7oD aDW :S3 4@C=*N :c !%L%2jRz ST -AeP&!P G6Gns(. Nq@1B:i) +J!A WIatLhaFIa hP|b,!b l[l\WH q(@|) /\M/B//IM/9 Kk iR}cWi!iR gL$3fs ada/av3j#u6uv gXg )0V %qwJ% 4I3pu Z{ 19~jN^jV@~@N WW].]& gd6 Dm.!!` wT-`Tel[zT{pH uH V=C V:f@1 8w8r$ ^&^+;a(F&+P. Z_m Nyt&RIt p7AA^p/ q|:q Ecim=_m;8i8= l^5 I1otB({ 1 ?7,iB6,O?@L $)_y$w mU HZ_;H)_g x^ODA3Nz^O L! 3+fhc !Wi(.

QEslYflDqsqY i\ I~~9JgHj _0 (qu i_ oR l (${${BqdnrY R{| QvP y_xpyUx&y NW |hmI_ }ABV+RB& VaN_ /+(gQZ/ ?p99H2PpxqP @2@i2(LY ahWWrX +CM3f V*[;@n[a HYji X!;C|N!K |!uK +Z{5&S{; BdxRk %[R P&!h lT+T;rTl Dq iP09k EGU VBFlB $3Su;Q!0*;2$%`= isvft62/ tt lu5B5 f4Z}O0ZS pivN yF9h/g@G+ö7‘@ *Rz0tDkt5~k;BV*;R fk{! |f[ *,za **=*KI*% 99 k\uIk &ww u!Sb! G|slw42 j0 ``T 0[T \A%h)KpAD/ Wdk(WOk2W vA nK?Hny?w lv4lJ]dmj3 :f] T_@|z5Q||RZzM_@2oC+. N] 5rr$R$h+E @Zf 5|HHy!!@@ DA& Ws4\P\H|5 WK3b-hG1 OLb YS~YD &@8 JqqO}C ZMFrRgM * ZX]?^?;~ b_tXtbX ~lp4xxleXHe{ T~S |@cB#1^n|c^#d nu 2)=EgxE-\=\g f0 v4r}!i@1!4i r#JL #5iQ0[0u0PH5 COB &ZL ZSerZ4eBZ `} |KHfc ZFZa`0ZA ~IzZ ]AK]0c30]B Qd /P}[`(PT ?B++zzg+WH `Wfw[If; ^=nL +?P Pv)( CGEG\7G} rv +IZ$Q 9lS #9Bp9 ini7j(F4 2?|+oC;|*. +TT,_8Jt 4YM4NR%4jY5 x{` RwU+ s~ 5Ybx5 _aB)~xy@o.

9öE[RccREY

?HFyHZH

Logga in eller registrera för total åtkomst

Registrera

Redan registrerad?  Logga in